Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | AOC1 | P19801 | 3/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714331 | 1.00 | KMT2A (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL26090940 | 0.94 | MERTK (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL22184593 | 0.87 | KMT2A (0.51) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL24496115 | 0.86 | KMT2A (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL22184570 | 0.86 | KMT2A (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL29714339 | 0.86 | KMT2A (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL2622288 | 0.86 | GABBR2 (0.47) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4711841 | 0.85 | GABBR2 (0.46) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL4713140 | 0.85 | GABBR2 (0.46) | KMT2AMEN1GABBR2CYP1A2CYP2C9 | |
| SCHEMBL6944164 | 0.84 | KMT2A (0.48) | KMT2AMEN1GABBR2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-116529251-A | Substituted fused bicyclic compounds as kinase inhibitors and their use | 上海瑛派药业有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116943-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | 上海瑛派药业有限公司 | 2022-06-09 | — | — | WO | disclosed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | KMT2A 2878/4885MEN1 4287/4885GABBR2 4509/4885 |
| US-20240124464-A1 | SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF | NUAK1, NUAK2, NEK11 | KMT2A 897/4885MEN1 1440/4885GABBR2 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.